ライフサイエンスコーパス: velpatasvir

1 r 400 mg plus velpatasvir 100 mg (sofosbuvir-velpatasvir).

2 sbuvir-daclatasvir is superior to sofosbuvir-velpatasvir).

3 ng those who received 24 weeks of sofosbuvir-velpatasvir.

4 of those who received 24 weeks of sofosbuvir-velpatasvir.

5 sofosbuvir plus ribavirin, and 15 sofosbuvir/velpatasvir.

6 r-daclatasvir was non-inferior to sofosbuvir-velpatasvir.

7 sus HIV/HCV coinfection receiving sofosbuvir-velpatasvir.

8 er 12 weeks of treatment with sofosbuvir and velpatasvir.

9 atasvir-voxilaprevir and 90% with sofosbuvir-velpatasvir.

10 d 96.5% (95% CI, 88.1-99.0%) with sofosbuvir/velpatasvir.

11 sofosbuvir combined with the NS5A inhibitor velpatasvir.

12 buvir-daclatasvir) or sofosbuvir 400 mg plus velpatasvir 100 mg (sofosbuvir-velpatasvir).

13 -dose combination of sofosbuvir (400 mg) and velpatasvir (100 mg) once daily for 12 weeks, sofosbuvir

14 ll patients received sofosbuvir (400 mg) and velpatasvir (100 mg) plus GS-9857 (100 mg) once daily.

15 inistered a combined sofosbuvir (400 mg) and velpatasvir (100 mg) tablet once daily for 12 weeks.

16 velpatasvir, 25 mg, and 100% (28 of 28) with velpatasvir, 100 mg, for genotype 1; 93% (25 of 27) in b

17 velpatasvir, 25 mg, and 95% (21 of 22) with velpatasvir, 100 mg, for genotypes 2, 4, 5, and 6.

18 velpatasvir, 100 mg; and 88% (23 of 26) with velpatasvir, 100 mg, plus ribavirin.

19 velpatasvir, 100 mg; and 81% (25 of 31) with velpatasvir, 100 mg, plus ribavirin.

20 Twelve weeks of sofosbuvir, 400 mg, and velpatasvir, 100 mg, was well-tolerated and resulted in

21 , 25 mg, plus ribavirin; 90% (26 of 29) with velpatasvir, 100 mg; and 81% (25 of 31) with velpatasvir

22 , 25 mg, plus ribavirin; 88% (23 of 26) with velpatasvir, 100 mg; and 88% (23 of 26) with velpatasvir

23 ir-voxilaprevir (163 patients) or sofosbuvir-velpatasvir (151 patients) for 12 weeks.

24 patients who received 12 weeks of sofosbuvir-velpatasvir, 16% of those who received 12 weeks of sofos

25 part A, SVR12 rates were 96% (26 of 27) with velpatasvir, 25 mg, and 100% (28 of 28) with velpatasvir

26 oups for genotype 3; and 96% (22 of 23) with velpatasvir, 25 mg, and 95% (21 of 22) with velpatasvir,

27 with velpatasvir, 25 mg; 88% (22 of 25) with velpatasvir, 25 mg, plus ribavirin; 88% (23 of 26) with

28 with velpatasvir, 25 mg; 83% (25 of 30) with velpatasvir, 25 mg, plus ribavirin; 90% (26 of 29) with

29 type 1, SVR12 rates were 87% (26 of 30) with velpatasvir, 25 mg; 83% (25 of 30) with velpatasvir, 25

30 type 2, SVR12 rates were 77% (20 of 26) with velpatasvir, 25 mg; 88% (22 of 25) with velpatasvir, 25

31 andomly assigned to sofosbuvir, 400 mg, with velpatasvir, 25 or 100 mg, for 12 weeks.

32 randomly assigned to sofosbuvir, 400 mg, and velpatasvir, 25 or 100 mg, with or without ribavirin for

33 First line regimens included: sofosbuvir/velpatasvir (27.3%), sofosbuvir/ledipasvir (26.5%), graz

34 35 patients who previously failed sofosbuvir/velpatasvir, 31 (88.5%) achieved SVR compared to 92 of 9

35 ients who received treatment with sofosbuvir-velpatasvir, 34% had HCV genotype 1a, 19% genotype 1b, 1

36 All patients received sofosbuvir-velpatasvir (400 mg/100 mg fixed-dose combination tablet

37 tember 1, 2015, patients received sofosbuvir-velpatasvir (400 mg/100 mg in a fixed-dose combination)

38 ty of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg/100 mg) plus weight-adjusted ribavir

39 NS5A inhibitor (daclatasvir, ledipasvir, or velpatasvir), 5 (38.5%) also harbored NS5B S282C/T RASs

40 nce interval [CI]: 62.0-92.0) for sofosbuvir/velpatasvir, 81.0% (95% CI: 67.0-93.0) for sofosbuvir/da

41 cohort 2, SVR12 rates were 58% with 25 mg of velpatasvir, 84% with 25 mg of velpatasvir plus ribaviri

42 patients who received 12 weeks of sofosbuvir-velpatasvir, 94% (95% CI, 87 to 98) among those who rece

43 cohort 1, SVR12 rates were 85% with 25 mg of velpatasvir, 96% with 25 mg of velpatasvir plus ribaviri

44 ohort 3, SVR12 rates were 100% with 25 mg of velpatasvir, 97% with 25 mg of velpatasvir plus ribaviri

45 Sofosbuvir-velpatasvir, a pangenotypic direct-acting antiviral regi

46 buvir, ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir achieved high SVR rates with good safety pro

47 nstructural protein 5A (HCV NS5A) inhibitors velpatasvir and elbasvir.

48 ary pan-genotypic combinations of sofosbuvir-velpatasvir and glecaprevir-pibrentasvir, have been show

49 Only velpatasvir and pibrentasvir had uniform high activity a

50 given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, i

51 transplantation, past exposure to sofosbuvir/velpatasvir and/or complex resistance profiles.

52 patasvir plus ribavirin, 100% with 100 mg of velpatasvir, and 100% with 100 mg of velpatasvir plus ri

53 lpatasvir plus ribavirin, 88% with 100 mg of velpatasvir, and 96% with 100 mg of velpatasvir plus rib

54 patasvir plus ribavirin, 100% with 100 mg of velpatasvir, and 96% with 100 mg of velpatasvir plus rib

55 Four weeks of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 in 4 of 15 (2

56 reatment with the combination of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 in most treat

57 ledipasvir, ombitasvir, elbasvir, ruzasvir, velpatasvir, and pibrentasvir in cultured cells infected

58 ties of glecaprevir/pibrentasvir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir in

59 ase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 i

60 ase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 i

61 ase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor voxilaprevir (15

62 mpare sofosbuvir-daclatasvir with sofosbuvir-velpatasvir, and to evaluate potential novel treatment s

63 nts received a 12-weeks course of sofosbuvir/velpatasvir at entry.

64 r pack of 400 mg of sofosbuvir and 100 mg of velpatasvir at time of HCV RNA results disclosure.

65 basvir, but equally sensitive to ombitasvir, velpatasvir, beclabuvir, dasabuvir, MK-3682, and sofosbu

66 Two patients receiving sofosbuvir-velpatasvir, both with HCV genotype 1, had a virologic r

67 uvir, GS-331007 (sofosbuvir metabolite), and velpatasvir concentrations in breast milk were 13%, 1.2%

68 shown to be highly resistant to daclatasvir, velpatasvir, elbasvir, and pibrentasvir.

69 ur patented brand-name drugs (sofosbuvir and velpatasvir fixed-dose combination tablets [Epclusa], le

70 ssigned in a 1:1 ratio to receive sofosbuvir-velpatasvir for 12 weeks (277 patients) or sofosbuvir-ri

71 In patients given sofosbuvir and velpatasvir for 12 weeks (n=90), clinically significant

72 udy evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2,

73 er phase 3 studies, single-tablet sofosbuvir-velpatasvir for 12 weeks is an efficacious and safe trea

74 Once-daily sofosbuvir-velpatasvir for 12 weeks provided high rates of sustaine

75 Sofosbuvir-velpatasvir for 12 weeks was safe and provided high rate

76 ent with 400 mg of sofosbuvir plus 100 mg of velpatasvir for 12 weeks was well-tolerated and highly e

77 ir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but the 2 regimens had similar

78 asvir-voxilaprevir for 8 weeks or sofosbuvir-velpatasvir for 12 weeks.

79 ection drug use were treated with sofosbuvir-velpatasvir for 12-weeks and offered buprenorphine initi

80 re observed in patients given sofosbuvir and velpatasvir for 24 weeks (n=90).

81 t ribavirin for 12 weeks and with sofosbuvir-velpatasvir for 24 weeks resulted in high rates of susta

82 r plus ribavirin for 12 weeks, or sofosbuvir-velpatasvir for 24 weeks.

83 or 1200 mg) for 12 weeks, or sofosbuvir and velpatasvir for 24 weeks.

84 genotype 3, who was treated with sofosbuvir/velpatasvir for 6 weeks.

85 inhibitor sofosbuvir and the NS5A inhibitor velpatasvir for HCV in patients coinfected with HIV-1.

86 e-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not

87 (95%) of 307 participants in the sofosbuvir-velpatasvir group (risk difference 2.2%, 90% credible in

88 ported in 15 patients (2%) in the sofosbuvir-velpatasvir group and none in the placebo group.

89 1 [4%] of 313 participants in the sofosbuvir-velpatasvir group vs six [2%] of 311 in the sofosbuvir-d

90 stained virologic response in the sofosbuvir-velpatasvir group was 95% (95% CI, 92 to 98), which was

91 stained virologic response in the sofosbuvir-velpatasvir group was 99% (95% confidence interval [CI],

92 mization but were assigned to the sofosbuvir-velpatasvir group.

93 sofosbuvir and ledipasvir or sofosbuvir and velpatasvir had decreased efficacy against infection wit

94 Treatment with combined sofosbuvir and velpatasvir has resulted in high sustained virological r

95 inhibitor sofosbuvir and the NS5A inhibitor velpatasvir in a once-daily, fixed-dose combination tabl

96 ssigned in a 1:1 ratio to receive sofosbuvir-velpatasvir, in a once-daily, fixed-dose combination tab

97 individuals treated for HCV with sofosbuvir-velpatasvir, including those with highly diverse viral g

98 pproved hepatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) might inhibit SARS-CoV-2.

99 dipasvir/sofosbuvir (n = 197), or sofosbuvir/velpatasvir (n = 57), with or without ribavirin in 12 ce

100 inhibitor sofosbuvir and the NS5A inhibitor velpatasvir once daily for 12 weeks, sofosbuvir-velpatas

101 All patients received sofosbuvir-velpatasvir once daily for 12 weeks.

102 ch cohort were randomly assigned to 25 mg of velpatasvir once daily with or without ribavirin or 100

103 daily with or without ribavirin or 100 mg of velpatasvir once daily with or without ribavirin.

104 Participants received sofosbuvir/velpatasvir (once daily; SIMPLIFY) or paritaprevir/riton

105 Participants received sofosbuvir/velpatasvir (once-daily; SIMPLIFY) or paritaprevir/riton

106 notypic direct-acting antivirals (sofosbuvir-velpatasvir or glecaprevir-pibrentasvir) despite the pre

107 (SVR12) with a 12-week course of sofosbuvir-velpatasvir or sofosbuvir-ledipasvir, with or without ri

108 ting 2 or more 28-pill bottles of sofosbuvir-velpatasvir (P < .001) and receiving OAT at week 24 (P =

109 ype of RASs in combination with daclatasvir, velpatasvir, pibrentasvir, elbasvir, and sofosbuvir was

110 hase 2 open-label trial, we found sofosbuvir-velpatasvir plus GS-9857 (8 weeks in treatment-naive pat

111 e found 8 weeks of treatment with sofosbuvir-velpatasvir plus GS-9857 to be safe and effective in tre

112 mg) once daily for 12 weeks, sofosbuvir and velpatasvir plus oral ribavirin (weight-based 1000 mg or

113 In patients given sofosbuvir and velpatasvir plus ribavirin (n=87), PRO scores decreased

114 patasvir once daily for 12 weeks, sofosbuvir-velpatasvir plus ribavirin for 12 weeks, or sofosbuvir-v

115 ng antiviral-based therapies with sofosbuvir-velpatasvir plus ribavirin for 24 weeks was well tolerat

116 with 25 mg of velpatasvir, 96% with 25 mg of velpatasvir plus ribavirin, 100% with 100 mg of velpatas

117 with 25 mg of velpatasvir, 97% with 25 mg of velpatasvir plus ribavirin, 100% with 100 mg of velpatas

118 with 25 mg of velpatasvir, 84% with 25 mg of velpatasvir plus ribavirin, 88% with 100 mg of velpatasv

119 of those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 18% of those who receive

120 ng those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 86% (95% CI, 77 to 92) a

121 00 mg of velpatasvir, and 96% with 100 mg of velpatasvir plus ribavirin.

122 0 mg of velpatasvir, and 100% with 100 mg of velpatasvir plus ribavirin.

123 00 mg of velpatasvir, and 96% with 100 mg of velpatasvir plus ribavirin.

124 of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A protease inhibi

125 cant difference in SVR was found by baseline velpatasvir RAS.

126 inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologi

127 hosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic res

128 We describe a government sofosbuvir/velpatasvir + ribavirin (SOF/VEL + RBV) x 24 weeks retre

129 2016-2017, participants received sofosbuvir/velpatasvir (SIMPLIFY) or paritaprevir/ritonavir/dasabuv

130 ect-acting antiviral therapy with sofosbuvir/velpatasvir (SOF/VEL [Epclusa]).

131 RBV-free pan-genotypic regimen with SOF and velpatasvir (SOF/VEL) on patient-reported outcomes (PROs

132 nts with 2- to 4-day pangenotypic sofosbuvir/velpatasvir (SOF/VEL) perioperative prophylaxis, where o

133 fibrosis on the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) treatment is limited in the Asian

134 After initial HERO Study sofosbuvir/velpatasvir (SOF/VEL) treatment, participants eligible f

135 r/pibrentasvir (GLE/PIB; n = 54), sofosbuvir/velpatasvir (SOF/VEL; n = 54), and ledipasvir/sofosbuvir

136 hepatitis C virus treatment with sofosbuvir/velpatasvir, sofosbuvir, GS-331007 (sofosbuvir metabolit

137 pproved Hepatitis C therapeutics Epclusa(R) (velpatasvir/sofosbuvir) and Zepatier(R) (elbasvir/grazop

138 -nine (79%) completed 12 weeks of sofosbuvir-velpatasvir treatment, 2 stopped treatment because of lo

139 which was judged to be related to sofosbuvir-velpatasvir treatment.

140 to SVV in 26 patients due to past sofosbuvir/velpatasvir use (n = 8), complex resistance associated s

141 asvir-voxilaprevir to 12 weeks of sofosbuvir-velpatasvir using a noninferiority margin of 5%.

142 he pharmacokinetics (PK) of sofosbuvir (SOF)/velpatasvir (VEL) in pregnant versus nonpregnant people.

143 mized controlled trial testing 2 (sofosbuvir-velpatasvir) versus 3 (sofosbuvir-velpatasvir-voxilaprev

144 pe 1 or 4) and retreatment with sofosbuvir + velpatasvir + voxilaprevir in case of virological failur

145 ssigned in a 1:1 ratio to receive sofosbuvir-velpatasvir-voxilaprevir (163 patients) or sofosbuvir-ve

146 this Phase 2, multicenter study, sofosbuvir-velpatasvir-voxilaprevir 400/100/100 mg daily was admini

147 interval [CI], 86-100) receiving sofosbuvir-velpatasvir-voxilaprevir alone and 24 of 25 (96%; 95% CI

148 e most commonly reported AEs with sofosbuvir-velpatasvir-voxilaprevir alone were diarrhea and bronchi

149 the rate of response was 98% with sofosbuvir-velpatasvir-voxilaprevir and 90% with sofosbuvir-velpata

150 Sofosbuvir-velpatasvir-voxilaprevir exposures were similar to those

151 assigned randomly to groups given sofosbuvir-velpatasvir-voxilaprevir for 8 weeks or sofosbuvir-velpa

152 ection, we did not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to

153 4 infection were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group.

154 14 patients) were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group.

155 efficacy, and pharmacokinetics of sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years w

156 Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for c

157 In Europe, sofosbuvir-velpatasvir-voxilaprevir is also indicated in the absenc

158 The pangenotypic regimen of sofosbuvir-velpatasvir-voxilaprevir is highly efficacious and well-

159 In the USA and Europe, sofosbuvir-velpatasvir-voxilaprevir once daily for 12 weeks is indi

160 diarrhea and bronchitis; and with sofosbuvir-velpatasvir-voxilaprevir plus RBV were fatigue, anemia,

161 Sofosbuvir-velpatasvir-voxilaprevir taken for 12 weeks provided hig

162 None of the patients discontinued sofosbuvir-velpatasvir-voxilaprevir therapy because of an adverse e

163 the noninferiority of 8 weeks of sofosbuvir-velpatasvir-voxilaprevir to 12 weeks of sofosbuvir-velpa

164 A fixed-dose combination of sofosbuvir-velpatasvir-voxilaprevir was well tolerated and effectiv

165 fixed-dose combination tablet of sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin (RBV)

166 sofosbuvir-velpatasvir) versus 3 (sofosbuvir-velpatasvir-voxilaprevir) DAAs.

167 protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).

168 d virologic response was 96% with sofosbuvir-velpatasvir-voxilaprevir, as compared with 0% with place

169 1a infection receiving 8 weeks of sofosbuvir-velpatasvir-voxilaprevir.

170 patients had an SVR to 8 weeks of sofosbuvir-velpatasvir-voxilaprevir; this did not meet the criterio

171 rug Administration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) fixed-do

172 rials, HCV salvage treatment with Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) achieved an SVR12

173 irus (HCV) salvage treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) achieved an SVR12

174 Sofosbuvir/velpatasvir/voxilaprevir (SVV) is recommended as the fir

175 svir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir in cell culture, and how the HC

176 Sofosbuvir/velpatasvir/voxilaprevir is recommended for hepatitis C

177 in 93.0% (95% CI: 83.0-99.0) for sofosbuvir/velpatasvir/voxilepravir and in 100% (95% CI: 92.0-100)

178 response among patients receiving sofosbuvir-velpatasvir was 99% (95% confidence interval, 98 to >99)

179 Among these inhibitors, velpatasvir was more effective against variants with RAS

180 after antiviral therapy with sofosbuvir and velpatasvir, we found that intrahepatic MAIT cells are a

181 , emtricitabine, sofosbuvir, ledipasvir, and velpatasvir were inactive at concentrations up to 10 uM.

182 ransitioned to insurance-provided sofosbuvir-velpatasvir when feasible to complete a 12-week treatmen

183 ish noninferiority to 12 weeks of sofosbuvir-velpatasvir, which produced an SVR in 98% of patients (9

184 n a fixed-dose combination of sofosbuvir and velpatasvir with and without ribavirin.

185 Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and w

186 plus the nonstructural protein 5A inhibitor velpatasvir with or without the nonstructural protein 3/

187 ated cirrhosis who were given sofosbuvir and velpatasvir without ribavirin.